Detalhe da pesquisa
1.
Sunitinib for metastatic renal cell carcinoma: Real world data from the STAR-TOR registry and detailed literature review.
Urol Int
; 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38310863
2.
Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry.
Future Oncol
; 17(18): 2325-2338, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33724867
3.
Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry.
Future Oncol
; 16(35): 2939-2948, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33021843
4.
Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma.
Future Oncol
; 16(29): 2307-2328, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32964728
5.
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Oncologist
; 21(1): 102-9, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26621039
6.
Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study.
BMC Cancer
; 15: 303, 2015 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25925846
7.
Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study.
Onkologie
; 36(3): 95-100, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23485996
8.
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass).
Eur Urol
; 84(6): 571-578, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37758574
9.
Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group).
Invest New Drugs
; 30(3): 1184-92, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21484249
10.
The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines.
Tumour Biol
; 33(3): 757-65, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22170433
11.
GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers.
BMC Cancer
; 12: 586, 2012 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23228169
12.
[Interdisciplinary recommendations for the treatment of advanced renal cell carcinoma]. / Interdisziplinäre Empfehlungen zur Behandlung des fortgeschrittenen Nierenzellkarzinoms.
Aktuelle Urol
; 53(5): 403-415, 2022 09.
Artigo
em Alemão
| MEDLINE | ID: mdl-34852368
13.
A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).
Oncol Res Treat
; 45(5): 272-280, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35045416
14.
Defining the critical hurdles in cancer immunotherapy.
J Transl Med
; 9: 214, 2011 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-22168571
15.
Downregulation of STAT3 signaling induces apoptosis but also promotes anti-apoptotic gene expression in human pancreatic cancer cell lines.
Tumour Biol
; 32(3): 493-500, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21174186
16.
Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.
Eur J Haematol
; 87(5): 426-33, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21749447
17.
Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview.
Expert Rev Anticancer Ther
; 21(11): 1273-1286, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34291700
18.
[Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma]. / Sunitinib - vom Paradigmenwechsel zu einem Therapiestandard beim metastasierten Nierenzellkarzinom (mRCC).
Onkologie
; 33 Suppl 1: 2-4, 2010.
Artigo
em Alemão
| MEDLINE | ID: mdl-20164668
19.
[Outlook: Future therapy of renal cell carcinoma]. / Ausblick: Therapie des Nierenzellkarzinoms von morgen.
Onkologie
; 33 Suppl 1: 18-20, 2010.
Artigo
em Alemão
| MEDLINE | ID: mdl-20164673
20.
[What is new in the diagnosis and therapy of renal cell carcinoma?] / Was ist neu bei der Diagnostik und Therapie des Nierenzellkarzinoms?
Dtsch Med Wochenschr
; 145(11): 734-739, 2020 06.
Artigo
em Alemão
| MEDLINE | ID: mdl-32492742